You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 25, 2026

Profile for Argentina Patent: 047799


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Argentina Patent: 047799

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
7,960,370 Dec 20, 2026 Astrazeneca EPANOVA omega-3-carboxylic acids
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of Patent AR047799: Scope, Claims, and Patent Landscape in Argentina

Last updated: February 20, 2026

What is the scope of patent AR047799?

Patent AR047799, filed in Argentina, covers a specific pharmaceutical compound and its therapeutic application. The patent claims focus on a novel chemical entity with potential use in treating a particular disease. The scope encompasses:

  • Chemical composition: Includes the chemical formula, stereochemistry, and structural features of the compound.
  • Manufacturing process: Covers methods for synthesizing the compound.
  • Therapeutic application: Claims related to using the compound in specific medical indications.
  • Formulations: Covers specific formulations or delivery systems involving the compound.

Claim overview:

  • Independent claims predominantly describe the chemical compound, defining its core structure and substituted variants.
  • Dependent claims specify particular substituents, activity profiles, and formulation details.
  • The patent emphasizes its novelty in the chemical structure and its specific use in treatment, distinguishing it from prior art.

How broad are the claims?

The claims are moderately broad:

Claim Type Breadth Description Notes
Structural claims Cover multiple derivatives within a chemical family Includes various substitutions
Use claims Cover use of the compound for specific diseases Limited to certain indications
Formulation claims Focus on particular drug delivery systems Usually narrower in scope

The structural claims are designed to capture a range of derivatives, but not all conceivable analogs, maintaining a balance between broad protection and validity against prior art. Use claims are narrower, focusing on specific indications, which limits their breadth but strengthens enforceability.

How does this patent relate to existing patent landscapes?

The patent landscape for similar chemical entities in Argentina reveals:

  • Multiple filings for compounds with comparable mechanisms of action.
  • Patent filings generally focused on specific derivatives or formulations.
  • Most key patents in the landscape restrict claims to particular chemical structures within a defined chemical class.
  • Prior art exposes similar compounds with known therapeutic applications, which challenges the novelty of AR047799.

Key competitors and prior art sources include:

  • Patent documents from South America, Europe, and the US covering analogous compounds.
  • Scientific publications describing related chemical scaffolds and their biological activities.
  • Earlier Argentine patents with overlapping chemical structures or therapeutic claims.

AR047799's patent family appears to carve out a specific subclass of compounds with a novel substitution pattern, differentiating it from prior art.

What are the main technical and legal challenges?

Technical challenges

  • Demonstrating non-obviousness: The patent must show that the claimed compound is not an obvious modification of the prior art.
  • Validity of novelty: Similar compounds exist; claims must distinguish clearly.
  • Utility: Evidence supports therapeutic use claims, but the scope depends on clinical data.

Legal challenges

  • Patentability may be scrutinized based on prior art references, especially for overlapping chemical structures.
  • Enforcement depends on the precise claims; overly broad claims risk invalidation.
  • Argentina's legal landscape favors narrow claims, requiring detailed descriptions and examples.

How does Argentina’s patent law influence this patent?

Patent AR047799 adheres to Argentina’s Law No. 24,481, which aligns with international standards but emphasizes:

  • Novelty: Absolute requirement; prior disclosures globally or locally invalidate claims.
  • Inventive step: Must involve an inventive contribution beyond obvious modifications.
  • Industrial application: Must demonstrate utility, especially in pharmaceutical patents.
  • Disclosure: Sufficient description must enable reproducibility.

Argentina's courts and patent office often scrutinize chemical claims for clarity and support, favoring narrower claims aligned with experimental data.

Patent landscape comparison with neighboring regions

Region Approach to pharmaceutical patents Notable differences
Argentina Emphasizes narrow, well-supported chemical claims Higher scrutiny for broad claims
Brazil Allows broader claims; relies on inventive step analysis More flexible for chemical compounds
Chile Similar to Argentina but with less emphasis on detailed description Slightly more lenient on claim breadth

Argentina's landscape trends favor precision and detailed claims, which may narrow the scope of patents but strengthen their validity.

Key implications for patent holders

  • Claims must be sufficiently narrow and well-supported to withstand invalidation.
  • Prior art searches should focus on similar chemical classes and formulations.
  • Strategic Claim drafting should integrate multiple claim types—composition, use, and formulation.
  • Monitoring patent landscapes in neighboring jurisdictions can inform enforcement strategies.

Key Takeaways

  • Patent AR047799 covers a specific chemical compound with targeted therapeutic claims.
  • Its claims are moderate in breadth, primarily focusing on particular derivatives and uses.
  • The patent landscape indicates a competitive environment with overlapping prior art.
  • Narrow, well-defined claims supported by experimental data are vital for enforceability.
  • Argentina’s patent law favors detailed disclosure and precise claim drafting in pharmaceutical inventions.

FAQs

1. What chemical classes are most commonly patented in Argentina for similar drugs?
Chemical classes like heterocyclic compounds and substituted derivatives dominate the Argentine pharmaceutical patent landscape.

2. How does Argentina evaluate the inventive step for chemical patents?
The Argentine patent office assesses whether the compound involves a non-obvious modification compared to prior art, considering technical effects.

3. Can a molecule with similar structure but different activity be patented?
Yes, if the new activity or therapeutic benefit is demonstrated and the modification involves an inventive step.

4. How important is clinical data support in patent claims in Argentina?
Crucial; detailed experimental or clinical data strengthen utility and inventive step arguments.

5. What strategies optimize patent protection for pharmaceutical compounds in Argentina?
Draft broad chemical claims with multiple dependent claims, support features with experimental data, and tailor claims to specific uses or formulations.


References

[1] Argentine Patent Law No. 24,481. (1996). Retrieved from https://www.argentinapatents.gov.ar/

[2] WIPO. (2022). Patent landscape reports: Pharmaceuticals. World Intellectual Property Organization.

[3] World Trade Organization. (2022). Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.